p63 shRNA Vector for Cardiac Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for cardiac tissue repair, such as reprogramming fibroblasts into cardiomyocytes, face low efficiency due to challenges in effectively downregulating or inactivating p63, p53, and p21, which are crucial for enhancing the reprogramming efficiency of cardiac cells.
Innovation Solution
The use of nucleic acid vectors containing agents like siRNA or shRNA to partially or completely downregulate p63, p53, and p21, combined with cardiac cell reprogramming factors like Hand2, myocardin, and miRNAs, to enhance the transdifferentiation of fibroblasts into cardiomyocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If transcription factors (Gata4, Mef2c, Tbx5) are used to reprogram fibroblasts into cardiomyocytes, then cardiac cell reprogramming is achieved, but reprogramming efficiency remains low
Solution Approach 1:
The patent extracts and removes the inhibitory factors (p63, p53, p21) that prevent efficient reprogramming. By using RNA interference to specifically target and silence these negative regulators, the invention isolates and eliminates the obstacles blocking high-efficiency reprogramming, thereby resolving the contradiction between achieving reprogramming and maintaining low efficiency
Solution Approach 2:
The invention changes the regulatory parameters of cell reprogramming by modulating the expression levels of key genes. Through RNA interference against p63, p53, and p21, the patent alters the cellular state from a low-reprogramming-efficiency state to a high-reprogramming-efficiency state, enabling effective therapeutic application
2Productivity
If p63, p53, and p21 are downregulated to enhance reprogramming efficiency, then cardiac cell transdifferentiation improves, but cellular control and regulation become more difficult
Solution Approach 1:
The patent introduces RNA interference molecules (siRNA, shRNA) as intermediary agents that mediate the downregulation of p63, p53, and p21. These intermediaries provide precise and controlled suppression of target genes, allowing efficient transdifferentiation while maintaining regulatory control through sequence-specific binding and inducible expression systems
Solution Approach 2:
The invention performs preliminary downregulation of inhibitory factors before initiating full reprogramming. By pre-silencing p63, p53, and p21 expression, the patent prepares the cellular environment to be more receptive to reprogramming signals, thereby enhancing subsequent transdifferentiation efficiency while maintaining manageable regulatory complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the efficiency of cardiac cell reprogramming, as demonstrated by the 45% expression of cardiac Troponin T in p63 knockout mouse embryonic fibroblasts, offering a promising therapeutic intervention for cardiac medical conditions like heart failure and cardiomyopathy.
Implementation Method 1
The use of nucleic acid vectors containing agents like siRNA or shRNA to partially or completely downregulate p63, p53, and p21
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.